Birdwatch Note
2023-04-03 14:54:52 UTC - MISINFORMED_OR_POTENTIALLY_MISLEADING
Ivermectin has no efficacy for COVID-19 based on randomized controlled trials. C19ivm does not include protocol registration w/methods, search strategies, inclusion criteria, quality assessment of the included studies nor the certainty of the evidence of pooled estimates. https://ebm.bmj.com/content/27/3/156 https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD015017.pub3/full
Written by 7554BE30DC1ACBA237371B5EFA9AFEE56A40F40178D64EB403F2D35E5AB5AD31
Participant Details
Original Tweet
Tweet embedding is no longer reliably available, due to the platform's instability (in terms of both technology and policy). If the Tweet still exists, you can view it here: https://twitter.com/foo_bar/status/1642802159111512064
Please note, though, that you may need to have your own Twitter account to access that page. I am currently exploring options for archiving Tweet data in a post-API context.
All Information
- ID - 1642903498466394112
- noteId - 1642903498466394112
- participantId -
- noteAuthorParticipantId - 7554BE30DC1ACBA237371B5EFA9AFEE56A40F40178D64EB403F2D35E5AB5AD31 Participant Details
- createdAtMillis - 1680533692362
- tweetId - 1642802159111512064
- classification - MISINFORMED_OR_POTENTIALLY_MISLEADING
- believable -
- harmful -
- validationDifficulty -
- misleadingOther - 0
- misleadingFactualError - 1
- misleadingManipulatedMedia - 0
- misleadingOutdatedInformation - 0
- misleadingMissingImportantContext - 0
- misleadingUnverifiedClaimAsFact - 0
- misleadingSatire - 0
- notMisleadingOther - 0
- notMisleadingFactuallyCorrect - 0
- notMisleadingOutdatedButNotWhenWritten - 0
- notMisleadingClearlySatire - 0
- notMisleadingPersonalOpinion - 0
- trustworthySources - 1
- summary
- Ivermectin has no efficacy for COVID-19 based on randomized controlled trials. C19ivm does not include protocol registration w/methods, search strategies, inclusion criteria, quality assessment of the included studies nor the certainty of the evidence of pooled estimates. https://ebm.bmj.com/content/27/3/156 https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD015017.pub3/full
Note Status History
createdAt | timestampMillisOfFirstNonNMRStatus | firstNonNMRStatus | timestampMillisOfCurrentStatus | currentStatus | timestampMillisOfLatestNonNMRStatus | mostRecentNonNMRStatus | participantId |
2023-04-03 14:54:52 UTC (1680533692362) |
1969-12-31 23:59:59 UTC (-1) |
2023-04-04 02:08:15 UTC (1680574095414) |
NEEDS_MORE_RATINGS | 1969-12-31 23:59:59 UTC (-1) |
Note Ratings
rated at | rated by | |
2023-04-04 04:21:41 -0500 | Rating Details | |
2023-04-03 21:10:48 -0500 | Rating Details | |
2023-04-03 19:40:18 -0500 | Rating Details | |
2023-04-03 19:26:33 -0500 | Rating Details | |
2023-04-03 16:33:41 -0500 | Rating Details | |
2023-04-03 16:18:44 -0500 | Rating Details | |
2023-04-03 15:56:30 -0500 | Rating Details | |
2023-04-03 15:26:21 -0500 | Rating Details | |
2023-04-03 15:19:30 -0500 | Rating Details | |
2023-04-03 15:06:50 -0500 | Rating Details | |
2023-04-03 14:53:04 -0500 | Rating Details | |
2023-04-03 14:40:49 -0500 | Rating Details | |
2023-04-03 14:26:59 -0500 | Rating Details | |
2023-04-03 14:24:57 -0500 | Rating Details | |
2023-04-03 14:11:54 -0500 | Rating Details | |
2023-04-03 14:10:32 -0500 | Rating Details | |
2023-04-03 14:00:25 -0500 | Rating Details | |
2023-04-03 13:36:02 -0500 | Rating Details | |
2023-04-03 12:40:34 -0500 | Rating Details | |
2023-04-03 12:01:33 -0500 | Rating Details | |
2023-04-03 11:22:58 -0500 | Rating Details | |
2023-04-03 10:45:44 -0500 | Rating Details | |
2023-04-03 10:29:30 -0500 | Rating Details | |
2023-04-03 10:23:03 -0500 | Rating Details | |
2023-04-03 10:14:33 -0500 | Rating Details | |
2023-04-03 10:13:12 -0500 | Rating Details | |
2023-04-03 10:00:07 -0500 | Rating Details | |
2023-04-09 17:04:15 -0500 | Rating Details | |
2023-04-03 14:24:57 -0500 | Rating Details | |
2023-04-03 10:00:07 -0500 | Rating Details | |
2023-04-03 10:23:03 -0500 | Rating Details | |
2023-04-03 15:06:50 -0500 | Rating Details | |
2023-04-03 15:26:21 -0500 | Rating Details | |
2023-04-03 19:40:18 -0500 | Rating Details | |
2023-04-03 14:11:54 -0500 | Rating Details | |
2023-04-03 10:45:44 -0500 | Rating Details | |
2023-04-03 15:19:30 -0500 | Rating Details | |
2023-04-03 13:36:02 -0500 | Rating Details | |
2023-04-03 10:29:30 -0500 | Rating Details | |
2023-04-03 14:26:59 -0500 | Rating Details | |
2023-04-03 12:01:33 -0500 | Rating Details | |
2023-04-03 14:10:32 -0500 | Rating Details | |
2023-04-03 14:40:49 -0500 | Rating Details | |
2023-04-09 17:04:15 -0500 | Rating Details | |
2023-04-04 04:21:41 -0500 | Rating Details | |
2023-04-03 19:26:33 -0500 | Rating Details | |
2023-04-03 14:53:04 -0500 | Rating Details | |
2023-04-03 16:18:44 -0500 | Rating Details | |
2023-04-03 16:33:41 -0500 | Rating Details | |
2023-04-03 11:22:58 -0500 | Rating Details | |
2023-04-03 15:56:30 -0500 | Rating Details | |
2023-04-03 14:00:25 -0500 | Rating Details | |
2023-04-03 10:14:33 -0500 | Rating Details | |
2023-04-03 10:13:12 -0500 | Rating Details | |
2023-04-03 12:40:34 -0500 | Rating Details | |
2023-04-03 21:10:48 -0500 | Rating Details |